| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H22N4O7 |
| Molecular Weight | 346.3364 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](OC)[C@H](O)CO
InChI
InChIKey=QNRRHYPPQFELSF-CNYIRLTGSA-N
InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1
Laninamivir (R-125489), a new neuraminidase (NA) inhibitor, was discovered, and in this study, its NA inhibitory activities against various influenza viruses including oseltamivir-resistant viruses are reported. Laninamivir octanoate, has been approved for use in Japanese clinics for the treatment and prevention of influenza in both adults and children. The inhaled laninamivir octanoate is converted into its active form, laninamivir, in the lungs where a high concentration persists for a long period of time.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
1. For treatment of the influenza virus
Adults: A single inhaled dose of 40 mg of laninamivir octanoate
Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate
If 10 years old or older, a single inhaled dose of 40 mg.
2. For prevention of the influenza virus
Adults and children over 10 years of age: Daily single inhaled dosage of 20 mg of laninamivir octanoate for two days
Route of Administration:
Respiratory
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
